Pehea e hoʻohana ai i ka lāʻau lapaʻau Liprimar 10?

Hoʻokumu ʻia ʻo Liprimar i ke ʻano o nā papa i pani ʻia me ka poni kiʻi ʻula: keokeo, ke ʻano elliptical, ma kahi wāhā - kahi keʻokeʻo keʻokeʻo, i kahakaha ʻia ma nā ʻaoʻao ʻelua i hilinaʻi ʻia i ka dosage - "10" a me "PD 155" / "20" a me "PD 156" / " 40 "a me" PD 157 "/" 80 "a me" PD 158 "(10 a 20 mg kēlā me kēia - 10 mau pcs. I nā blisters, 3 a me 10 mau paleka ma kahi pahu pahu, 7 pcs. nā pākeke, 40 a 80 mg i kēlā me kēia - 10 mau pcs i nā pōmole, 10 mau kihila i loko o ka pūlima kāleka, 7 mau pcs.

Aia ka hoʻonohonoho ʻana o ka papa pākuhi 1:

• ʻO ka mea kūpono: atorvastatin - 10, 20, 40 a i ʻole 80 mg (ma ke ʻano o ka paʻakai kalima),
• ʻO nā mea kōkua: calcium carbonate - 33/66/132/264 mg, cellulose microcrystalline - 60/120/240/480 mg, lōpose lactose - 32.8 / 65.61 / 131.22 / 262.44 mg, sodium croscarmellose - 9/18/36/72 mg, polysorbate 80 - 0.6 / 1.2 / 2.4 / 4.8 mg, hyprolose - 3/6 / 12/24 mg, magnesium stearate - 0.75 / 1.5 / 3/6 mg,
• Palani pale: Opadry keʻokeʻo YS-1-7040 (hypromellose - 66,12%, polyethylene glycol - 18,9%, titanium dioxide - 13.08%, talc - 1.9%) - 4.47 / 8.94 / 17 , 88 / 35.76 mg, emulsion of simethicone (simethicone - 30%, emearifier stearic - 0,075%, waikawa sorbic, wai) - 0,03 / 0,06 / 0.12 / 0.24 mg, ʻaila candelilla - 0, 08 / 0.16 / 0.32 / 0 mg.

Lapaʻau lāʻau

ʻO Atorvastatin he mea mālama i ka hoʻokūkū koho HMG-CoA reductase, kahi kīʻaha koʻikoʻi ia e hoʻohuli ana i ka 3-hydroxy-3-methylglutaryl-CoA i mevalonate, kahi mea i mua i ka steroid, e komo pū me ka kolamu. ʻO Liprimar e pili ana i nā lipid-hoʻohaʻahaʻa i nā kumu synthetic.

ʻO ka hoʻohana ʻana o ka atorvastatin i nā mea maʻi me ka dyslipidemia i hui ʻia, nā ʻano like ʻole familial o ka hypercholesterolemia, me ka heterozygous a me ka hypercholesterolemia familial homilialemia e alakaʻi i ka emi o ke kaila o ke koko o ka triglycerides (TG), haʻaheo haʻahaʻa lipoprotein cholesterol (ChL-VLDL-Ap, Apol) lipoprotein kūloko haʻahaʻa (cholesterol-LDL) a me ka nui o ka cholesterol (cholesterol). Eia nō hoʻi, i ka wā e lawe ai i ka Liprimar, hoʻonui i ke kīhāpai o ka kiʻekiʻe lipoprotein cholesterol (HDL-C).

Hoʻopili ke Atorvastatin i ka hana ʻana o ka kolamu ma ka puʻuwai, pale i ka hoʻōla o HMG-CoA, a ke hoʻonui nei i ka nui o nā receptors hepatic LDL ma nā pūlehu o nā pū o waho, kahi e alakaʻi ai i ka uptake a me ka catabolism o LDL-C a hāʻawi pū hoʻi i kahi hōʻemi o ka pae o ka kolamu a me LDL-C i ka plasma.

Hōʻemi ka liprimar i ka nui o nā palaka LDL a pale i ka hoʻokumu ʻana o ka LDL-C, alakaʻi i kahi hoʻonui nui mau a hoʻomau i ka hana o nā ʻĀina LDL, i hui pū ʻia me nā hoʻololi lula maikaʻi loa o nā palapoka LDL, a he hōʻemi nō hoʻi i ka pae o ka kolamu LDL i nā mea maʻi me ka hypercholesterolemia homozygous homediary e kū pono ana. hana me nā lāʻau lapaʻau lipid-hoʻoemi.

I ka wā i lawe ʻia ai ma ka nui o ka nui o 1080 mg, hoʻemi ka atorvastatin i ka hoʻōla ʻana o TG ma ka 14-33%, apo-B e 34–50%, kolamu-LDL e 41-61% a me ka kolamu ma ka 30-46%. Ane like nā hopena o ka hopena i nā mea maʻi me nā ʻohana ʻole o ka hypercholesterolemia, he hyperzolesterolemia ʻohana heterozygous a me ka hyperlipidemia i hui pū ʻia, me nā mea maʻi me ka diabetes type 2.

I ka poʻe maʻi me ka hypertriglyceridemia hoʻokaʻawale, ke hoʻohaʻahaʻa ka mea ikaika a Liprimara i ke kiʻekiʻe o TG, apo-B, cholesterol-VLDL, cholesterol-LDL a me ka kolamu nui a hoʻonui i ke kiʻekiʻe o ka cholesterol-HDL. I loko o nā mea maʻi me ka dysbetalipoproteinemia, i ka wā e lawe ai i Liprimar, ua hoʻemi ʻia ka ʻike ʻana i ke kūkaʻi lipoprotein cholesterol intermediate.

I nā maʻi me ka type IIa a me IIb hyperlipoproteinemia, e like me ka helu ʻana o Fredrickson no ka hoʻomaʻomaʻi atorvastatin (ke ʻano awelika 1080 mg), hoʻonui ʻia ka ʻike o HDL-C ma ka 5.1–8.7% hoʻohālikelike ʻia i ka waiwai mua, a ʻaʻole i hopena kēia hopena. he hilinai dosis. ʻO ka hoʻohālikelike o ka cholesterol-LDL / cholesterol-HDL a me ka nui o ka cholesterol-cholesterol-HDL i hoʻohaʻahaʻa nui ʻia (ʻo ka hoʻohaʻawale ʻia ʻana e ka ʻōpū o Liprimar i lawe ʻia) e 37-55% a me 29-44%, ia manawa. ʻO ka atorvastatin ma kahi o 80 mg ka hoʻohaʻahaʻa nui loa i ka hōʻemi ʻana i ka hoʻopiʻi ischemic hoʻopiʻi a hōʻemi i ka make ma ka 16% ma hope o ka hoʻopau ʻana i kahi papa lapaʻau o 16 wiki, a me ka pilikia o ka hoʻoliʻi hou ʻana i pili me ka angina pectoris, ka mea i hui pū ʻia e nā hōʻailona o ka ischemia myocardial, hōʻemi ʻia e 26% e like me ka noiʻi. , aia ka emi ʻana o ka hōʻeha o nā hōʻailona o ka ischemia myocardial i ka wā intensial lipid-lowering therapy (MIRACL). I nā mea maʻi me nā kiʻekiʻe mua o ka LDL-C, nā mea maʻi me ka angststable angina a me ka myocardial infarction me ka pā ʻole o Q ma kahi o ke kāne (male a me ka wahine) a me nā makahiki (ʻōpio a ʻoi aku ka makahiki he 65 mau makahiki), ka lawe ʻana i ka atorvastatin i ka hopena o ka hōʻeha o ka hoʻopiʻi ischemic a me ka make. ʻO ka emi ʻana o ka neʻe o ka LDL-C i ka plasma e hōʻike ana i kahi kaila maikaʻi loa me ka hopena o Liprimar ma mua o ke ʻano o ka hana i ka hana i loko o ke koko koko. Pono e koho ʻia ka nui ʻōlelo ma ka hopena i ka hopena lapaʻau.

Hoʻopaʻa ʻia ka hopena therapeutic o Liprimar i 2 mau pule ma hope o ka hoʻomaka ʻana o ka mālama ʻana, hiki i kahi kiʻekiʻe ma hope o 4 mau wiki a hoʻomau i ka holo o ke ʻano.

I nā mea maʻi me ka hypertension arterial, a he ʻekolu a ʻoi aku paha nā mea e pono ai, e lawe ana i ka atorvastatin ma ke ʻano o 10 mg e hōʻemi i ka hopena o ka hoʻoulu ʻana i ka hōʻeha o ka puʻuwai kino (fatal) me nā pletebo. Hōʻike ʻia nā hualoaʻa o ka noi Anglo-Scandinavian e pili ana i ka hopena o ka hopena o ka maʻi ʻōpū (ASCOT-LLA), e like me ka lawelawe ʻana o Liprimar ma kahi o 10 mg e hōʻemi ana i ka hopena o kekahi mau hoʻopiʻi e like me kēia:

• ʻeha (non-fatal / fatal) - by 26%,
• nā hihia a ka coronary (non-fatal myocardial infarction a me ka maʻi ʻōpū coronary, i hele pū me ka make) - e 36%,
• nā maʻi hoʻopiʻi maʻamau - ma o 29%,
• nā maʻi hoʻopiʻi maʻamau a me nā ʻōnaehana revascularization - ma o 20%.

E like me nā hopena o kahi hōʻike ʻana i ka lawe ʻana i ka atorvastatin no ka maʻi diabetes mellitus type 2 (CARDS), ka hoʻohana ʻana o Liprimar i nā maʻi me kēia maʻi e hōʻemi ana i ka hopena o ka hoʻopiʻi cardiovascular pili ʻole ka makahiki a me nā kāne a i ʻole ka hoʻomaka mua ʻana o LDL-C penei:

• ʻeha (non-fatal / fatal) - by 48%,
• ischemia myocardial ischemia, non-fatal (fatal) myocardial infarction - ma ka 42%,
• nā huaʻomekole cardiovascular nui (stroke, revascularization kaʻina, hōʻeha ʻole i ka myocardial ischemia, nonfatal a fatal myocardial infarction, percutaneous transluminal coronary angioplasty, died due to exacerbation of coronary heart disease, coronary artery bypass grafting, unstable angina pectoris) - na 37%.

Ke hōʻike nei i ka hopena o ka hopena hypolipidemic intensive ma ka hoʻohuli ʻana i ka corherary atherosclerosis (REVERSAL) i hōʻike ʻia mai nā mea maʻi me ka maʻi naʻau coronary e lawe ana i ka atorvastatin i kēlā me kēia lā o ka 80 mg kumu i ka hoʻemi ʻana i ka nui o ka nui o ka atheroma ma 0.4% ma hope o 1,8 mau mahina o ka mālama ʻana.

ʻO ka lawelawe ʻana o ka atorvastatin i loko o kēlā me kēia lā he 80 mg hiki i ka hōʻemi i ka hōʻemi ʻana i ka maʻi non-fatal (fatal) i nā mea maʻi i loaʻa i ka puʻuwai ischemic transient a stroke a me ka mōʻaukala o ka maʻi naʻau coronary hoʻohālikelike i ka placebo e like me nā hopena o kahi noiʻi ʻana i kahi hōʻeha me kahi neʻeha nui i ke kolamu (SPARCL). Hoʻemi iki kēia i ka hōʻeha o ka lalo o ka hoʻopiʻi cardiovascular a me ka pono no nā loiloi revascularization. ʻO ka emi ʻana o nā pilikia o nā pilikia o ka ʻōnaehana cardiovascular i ka wā e mālama ai me ka atorvastatin i mālama ʻia i nā pūʻulu āpau o nā maʻi, me ka ʻokoʻa ʻole e pili ana i nā mea maʻi me ka maʻi hemorrhagic mua a i ʻole mau.

I ka poʻe maʻi me ka maʻi puʻukui coronary, ka lawe ʻana iā Liprimar ma ke ʻano o ka 80 mg i hoʻohālikelike ʻia me ka nui o ka nui o ka nui o ka 10 mg e hoʻēmi ana i ka hōʻeha o nā hoʻopiʻi ʻana e like me kēia (e like me nā hopena o kahi hōʻike o ka mālama ʻana a TNT e hoʻokō hou i nā kamaʻili lipid hou)

• ka luna ʻānela angina pectoris - e 10,9%,
• hoʻopiʻi ka maʻi cardiovascular (non-fatal myocardial infarction a me ka maʻi naʻau coronary, i ukali ʻia me ka make) - e 8,7%,
• e pili ana i ke kaʻina hana a me ke kēkē hou
• non-fatal myocardial infarction, ʻaʻole i hoʻoneʻe ʻia e ke kaʻina hana - e 4.9%,
• wahi i loko o kahi hale hoʻomaha me ka puʻuwai naʻau congestive - e 2.4%,
• kaʻeha ʻole (hōʻeha) (2.3%).

E hoʻokuʻu i nā palapala a me ka ʻano

Loaʻa ka lāʻau lapaʻau i nā papa hana enteric-coated. ʻO ka pāʻina dosage ka 10 mg o ka atorvastatin calcium ma kahi ʻano ikaika. No ka wikiwiki o ka komo ʻana a me ka hoʻonui ʻana i ka bioavailability, ua pā ka papa i nā mea hou aku:

• mikuleka
• konekena stearate,
• waiū waiū
• Hoʻopiʻi
• sodium polio
• kalaka

ʻO ka hui pū ʻana o nā papa me ka cellulose microcrystalline, magnesium stearate, waiʻaila waiū, hyprolose, sodium croscarmellose, calcium carbonate.

ʻO ka membrane kiʻi'ōmaʻomaʻo i nā kākela candelilla, hypromellose, polyethylene glycol, talc, emulsion simethicone, titanium dioxide. Ma nā papa keʻokeʻo o ka ʻano elliptical, ua hoʻoili ʻia ke kālai "PD 155" a me kahi hoʻohālikelike o ke ʻano ikaika.

Ka hana lāʻau lapaʻau

ʻO Liprimar ka māhele o ka lāʻau lipid-hoʻemi haʻahaʻa. ʻO ka mea hoʻoneʻe atorvastatin ka mea koho blocker o HMG-CoA reductase, ka polokalamu nui pono e pono ai no ka hoʻololi ʻana o ka 3-hydroxy-3-methylglutaryl coenzyme i mevalonate.

Ma ka hiki ʻana o kahi ʻano hoʻoilina o ka hypercholesterolemia (hoʻonui i ka cholesterol), i hoʻohui ʻia o ka dyslipidemia, ke ʻano ikaika o Liprimara e kōkua i ka hoʻemi ʻana i ka plasma o ka kolamu o ka kolamu (Ch), apolipoprotein B, VLDL a me LDL (lipoproteins haʻahaʻa haʻahaʻa) a me ka nui o nā triglycerides. Hoʻokomo ʻia ʻo Atorvastatin i ka hoʻonuiʻana i ka lipoprotein density kiʻekiʻe (HDL).

ʻO ka hana o ka hana ma muli o ke kaohi ʻana o ka hana o HMG-CoA reductase a me ka pale ʻana i ka hoʻomohala kolé i ka hepatocytes.

Hiki i ke Atorvastatin ke hoʻonui i ka nui o nā mea hōʻemi lipoprotein haʻahaʻa haʻahaʻa ma ka ʻaoʻao o waho o ka membrane cell cell, e alakaʻi ai i ka uptake a me ka luku ʻana i ka LDL.

Hiki i ka lāʻau lapaʻau ke hoʻonui i ka nui o nā mea hōʻemi lipoprotein haʻahaʻa haʻahaʻa ma ka ʻaoʻao o waho o ka membrane cell cell.

Hoʻopili ka mea hana hoʻomehana i ka synthesis o LDL cholesterol a me ka nui o nā lipoproteins e hoʻopilikia ai, ma muli o ka mea i hoʻonui nui ʻia o ka hana o nā mea LDL. I ka poʻe maʻi me ka homozygous herpaio hypercholesterolemia kū i ke hana ʻana i ka wai lāʻau lipid-hoʻemi, hoʻēmi ʻia nā wae LDL. Hoʻomaopopo ka hopena therapeutic i loko o 2 mau pule ma hope o ka hoʻomaka ʻana o ka lāʻau lapaʻau. Ua hoʻopaʻa ʻia ka hopena kiʻekiʻe loa ma hope o hoʻokahi mahina o ka mālama ʻana me Liprimar.

Lapaʻau lāʻau

Ma hope o ka lawelawe waha, ʻaʻole i luku nā papa ma lalo o ka hana o ka waikawa hydrochloric i loko o ka ʻōpū, e hāʻule ana i ka jejunum proximal. Ma kēia ʻāpana o ka digestive tract, hoʻomaʻemaʻe ka membrane kiʻi i ka hydrolysis.

Ua wāwahi ka papa, nā mea kanu a me nā lāʻau lapaʻau e hoʻomaka i ke kūleʻa ma o ka microvilli kūikawā.

Hoʻokomo ʻia ʻo Atorvastatin i ke kahe koko mai ka paia ʻōpū, kahi i loaʻa ai i nā pae plasma nui loa i loko o 1-2 mau hola. I nā wahine, ʻo ka piʻi ʻana o ka waiwai ikaika he 20% kiʻekiʻe ma mua o nā kāne.

Ma hope o ka lawelawe waha, ʻaʻole palolo nā papa ma lalo o ka hana a ka hydrochloric acid i loko o ka ʻōpū.ʻO Liprimar 10 ke komo i ke kahe mai ka paia ʻōpū.
Hoʻopili ka mea ikaika o ka lāʻau i ka albumin e 98%, ʻo ia ke kumu he like ʻole ka hemodialysis.

Loaʻa ka bioavailability 14-30%. ʻO nā hōʻailona haʻahaʻa ma muli o ka metabolet ka parietal o atorvastatin i nā membous mucous o ka pāpīpī a me ka hoʻololi i loko o nā huina o ke akeʻa e ka isoenzyme o ka cytochrome CYP3A4. Hoʻopili ka mea ola i ka albumin e 98%, ʻo ia ke kumu he maikaʻi ʻole ai ka hemodialysis. ʻO ka hoʻopau pio-hapalua ke ola i nā hola 14. Hoʻomaopopo ka hopena therapeutic no 20-30 mau hola. Ma o ka urinary system, atorvastatin waiho i ke kino lohi - i loko o ka iomi, ma hope o hoʻokahi pālākiō, loaʻa wale nā ​​2% o ka maʻi.

Nā hōʻailona no ka hoʻohana ʻana

Hoʻohana ʻia ka lāʻau lapaʻau ma ka hana lapaʻau e mālama ai:

• ʻO ka hypercholesterolemia mua o ka hoʻoilina a me ke ʻano hoʻoilina,
• hoʻonui mahiki endogenous kūʻokoʻa o ka triglycerides kūʻai i ka lāʻauʻaiʻai,
• ʻO ka ʻōpiopio homozygous hypercholesterolemia me ka hana haʻahaʻa o nā meaʻai a me nā ʻano lāʻau ʻole hou no ka mālama ʻana,
• ua hui pū ʻia o ka hyperlipidemia.

ʻO ka lāʻau lapaʻau e kuhikuhi ʻia me ke ʻano pale no ka maʻi o ka naʻau i nā mea maʻi me nā hōʻailona ʻole o ka maʻi naʻau coronary, akā me nā mea pōpilikia: ka wā ʻelemakule, nā hana maikaʻi, ke koko kiʻekiʻe, ka maʻi mellitus. Hōʻuluʻulu ka mea pilikia i nā poʻe me kahi predisposition i ka hypercholesterolemia a me kahi haʻahaʻa o HDL.

Hāʻawi ʻia ka lāʻau lapaʻau e like me ke ʻano pale no ka maʻi naʻau.

Hoʻohana ʻia ka lāʻau lapaʻau e like me ke hoʻohui i ka lāʻauʻai no ka hoʻomohala ʻana o ka dysbetalipoproteinemia. Hoʻohana ʻia ka liprimar i mea e pale ai i ka hoʻomohala ʻana o nā hoʻopiʻi i ka poʻe maʻi me ka ischemia myocardial e hōʻemi i ka hopena o ka make, ka puʻuwai ʻeha, nā hōʻeha a me nā halemai ʻo ka angina pectoris.

Nā Hoʻohui

• ʻO nā maʻi maʻi neʻe a i ʻole ka hoʻonui ʻana i ka hana serum o nā transaminases (ʻoi aku ma mua o 3 mau manawa i ka hoʻohālikelike ʻia me ka palena palena palena o ke ʻano) o ka etiology ʻike ʻole,
• ʻAe a hiki i ka 18 mau makahiki (ma muli o ka lawa ʻole o ka ʻikepili ma luna o ka palekana a me ka hopena o Liprimar no kēia ʻano makahiki o nā maʻi),
• ʻŌpū a me ka lactation
• Hypersensitivity i ka lāʻau lapaʻau.

Relative (Liprimar e pono me ka mālama ʻana):

• Ka inu maikaʻi ʻana i ka waiʻona
• Nā hōʻikeʻike o ka mōʻaukala o nā maʻi maʻa.

I ka wā hana, pono nā wahine o ka hānau ʻana ke hoʻohana i nā ala kūpono o ka contraception.

Nā ʻōkuhi no ka hoʻohana Liprimar: kaʻina a me ka maʻi

Ma mua o ka hoʻohana ʻana iā Liprimar, pono ia e hoʻāʻo e hoʻokō i ka hoʻopaʻa ʻana o ka hypercholesterolemia me ka hoʻohana ʻana i ka meaʻai, ka hana kino a me ka hoʻolilo ʻana i ke kaumaha ma nā mea maʻi me ka huelo, me ka ʻōlelo no ka maʻi ma lalo.

I ke kuhikuhiʻana i ka lāʻau lapaʻau, pono e kuhikuhi ʻia ka mea maʻi e hahai i kahi kīʻai hypocholesterolemic maʻamau i ka papa holoʻokoʻa.

Lawe ʻia ʻia ʻo Liprimar, 1 manawa i kēlā me kēia lā, ʻaʻohe manaʻo o ka meaʻai a me ka wā o ka lā.

Wahi a ka ʻike ma mua o ka LDL-C, ke kumu o ka mālama a me ka pane ʻana o kēlā me kēia kanaka, ʻokoʻa ka pae ʻana mai ka 10 mg a 80 mg (kiʻekiʻe).

I ka hoʻomaka ʻana o ka lāʻau lapaʻau a me / a i ka manawa o ka hoʻonui ʻana i ka maʻa i kēlā me kēia mau hebedoma ʻo 2-4, pono ia e hoʻomalu i ka ʻike lipid plasma a, e like me kēia, e hana i ka hoʻoponopono hoʻoponopono ʻia.

No ka hapa nui o nā mea maʻi, ʻo ka nui o kēlā me kēia lā o Liprimar me ka hui pū ʻia me ka hyperlipidemia a me ka hypercholesterolemia mua he 10 mg. Ma ke kānāwai, hōʻike ʻia ka hopena therapeutic no 14 mau lā, e hōʻea ana i kahi nui loa i loko o hoʻokahi mahina. Me ka hopena lōʻihi, hoʻomau ka hopena.

Me ka hypercholesterolemia ʻohana homozygous, ua kuhikuhi ʻia ʻo Liprimar i loko o kēlā me kēia lā o 80 mg.

I ka poʻe maʻi me ka maʻi hepatic, e hōʻemi ʻia ka nui o ka lāʻau ma lalo o ka mālama mau ʻana i ka hana o aspartate aminotransferase a me alanine aminotransferase.

ʻAʻole hoʻopilikia ka pilikia o ka renal i hana i ka ʻike o ka atorvastatin i loko o ke kaila koko a i ʻole ka pae o ka hōʻemi i loko o ka ʻike o LDL-C, no laila, ʻaʻole pono nā mea maʻi e hoʻoponopono i ka lapaʻau.

Me ka hoʻomohala hoʻohālikelike ʻana me nā cyclosporine, ʻo ka nui loa o ke kiʻekiʻe loa o Liprimar he 10 mg.

Nā hopena hopena

E like me ke kānāwai, ua alakaʻi maikaʻi ʻia ʻo Liprimar, nā mea puka mai e neʻe aku ana a me ka ʻoluʻolu.

I ka wā o ka hōʻola, hiki i nā hopena kūpono ke ulu i (≥1% - pinepine, ≤1% - pinepine pinepine).

• ʻO nā ʻōnaehana o ka poepoe: pinepine - ka ʻeha, ka ʻāina, ka hopena no ka asomyic syndrome, ka maʻi maʻamau - peripheral neuropathy, dizziness, malaise, paresthesia, amnesia, hypesthesia,
• Pūnaehana Digestive: pinepine - constipation, dyspepsia, nausea, ʻeha ʻeha, ʻīwī, ʻōpū, ʻulaʻula, pinepine - anorexia, luaʻi, pancreatitis, hepatitis, cholestatic jaundice,
• Pūnaehana musculoskeletal: pinepine - myalgia, pinepine - ʻo myopathy, ʻeha hoʻi hope, ʻehaʻeha o ka naʻau, arthralgia, myositis, rhabdomyolysis,
• Hematopoietic ʻōnaehana: pinepine - thrombocytopenia,
• Metabolism: pinepine - hyperglycemia, hypoglycemia, hoʻonui i nā kiʻekiʻe o ka serum creatine phosphokinase,
• Nā maʻi alerine: pinepine - ka pākīnūnū epidermal epidermal (ʻelllelo o Lyell), ʻāwī ka ʻili, urticaria, pruritus, rash bullous, ʻano anaphylactic, erythema multiforme exudative (komo i nā Stevens-Johnson syndrome).
• Nā mea'ē aʻe: pinepine - hoʻonui i ka momona, peripheral edema, impotence, hōʻemi momona, tinnitus, ʻehaʻeha, hōʻeha o ka hana lua, alopecia.

Ke keu

ʻO nā hōʻailona o kahi overdose o atorvastatin ka nui o nā hopena hopena.

Inā e pono, e hoʻohālikelike i ka hana maʻi, mālama ʻia i ka hana a nā mea i hana ʻia ai ka phosphokinase a me nā hōʻike hana hoʻomaʻamaʻa maʻamau. No ka mea ke komo pū nei ka mea hana i nā hana i hoʻopaʻa ʻia ai i nā protein plasma, e noʻonoʻo ʻia ka hoʻohana ʻana o ka hemodialysis no kona excretion.

ʻAʻole maopopo ka antidote kikoʻī o ka atorvastatin.

Nā ʻōlelo kikoʻī

Ma hope o ka noi ʻana iā Liprimar, he ʻano maʻamau e hoʻonui ai i ka hana serum o ka alanine aminotransferase a me ka aspartate aminotransferase, he ulu pinepine mau ka serum pae o ka hepatic transaminases (me ka hoʻomohala ʻana o ka jaundice a i ʻole nā ​​hōʻike pilikino) ʻike ʻia. Me ka hoʻohaʻahaʻa ʻana i ka wai, hoʻihoʻi ʻia i ka lāʻau (ʻaʻole i paʻa a hoʻopau paha) ka hana o nā transaminases hepatic e hoʻi hou i ka pae mua. I ka nui o nā hihia, hiki i nā mea maʻi ke hoʻomau i ka maʻi ma kahi hōʻemi e loaʻa ʻole nā ​​hopena lapaʻau.

Pono nā loiloi o ka hana ate i nānā ʻia ma mua o ka mālama ʻana, 6 a me 12 mau pule ma hope o ka hoʻomaka ʻana o Liprimar a i ʻole ma hope o ka hoʻonui ʻana o ka waiū, me ka mahele o ka hopena o ka maʻi.

Hoʻokuʻu ʻia ka lāʻau lapaʻau me ka hoʻonui pinepine ʻia i ka hana o nā phosphokinase creatine, i mua i nā mea i manaʻoʻia a i ʻole i hoʻopaʻa ʻia myopathy. Ke koho ʻana i ka Liprimar i ka manawa like me ka immunosuppressants, hoʻonui i ka fibrates, erythromycin, nā lāʻau antifungal (azole derivatives) a i ka hopena nicotinic ma nā kūmole hypolipidemic, pono e noʻonoʻo ʻia ka nui o ka ulu ʻana o ka myopathy. Pono ka nānā ʻana o ke kūlana o ka mea maʻi e ʻike i ka nāwaliwali o ka naʻau a i ʻole ka hōʻeha ʻana, ʻoi loa hoʻi i nā mahina mua o ka lāʻau lapaʻau a i ka manawa o ka hoʻonui ʻana i nā dosis o kekahi lāʻau lapaʻau. Inā pono e mālama i ka hui hoʻohui, pono ia e noʻonoʻo i ka hiki ke hoʻohana ʻana i kēia mau lāʻau i ka wā haʻahaʻa a me nā papa mālama mālama.

Ke hoʻoili nei iā Liprimar, ua loaʻa nā hihia līlū o ka rhabdomyolysis me ka loaʻa ʻole o ka renal failed ma muli o ka myoglobinuria. Inā he mau hōʻailona o ka hiki aopala a i ʻole ka hopena o nā mea pili i ka hiki ʻole o ka renal ma muli o ka rhabdomyolysis (no ka laʻana, me ka maʻi ʻehaʻeha nui, hypotension arterial, trauma, metabolic, endocrine a me ka electrolyte hilahila a me nā kuʻekahi ākea, ʻoi aku ka nui o ka lawelawe) . ^ E Ha yM.

Inā ʻike ʻoe i ka nāwaliwali ʻole a maopopo ʻole i ka ʻehaʻeha o ka ʻili, ʻoiai inā ʻoe pū me ka maʻi a me ka malaise, pono ʻoe e ʻimi aku i kahi loea.

Hoʻokomo i ka hiki ke lawe i nā kaʻa a me nā mīkini paʻakikī

ʻAʻohe ʻike e pili ana i ka hopena o Liprimar i ka hiki ke hoʻokele i nā kaʻa a hoʻokō i nā ʻano mea e weliweli ai o ka hana e pono ai ka hoʻonui ʻana i ke neʻe a me nā hopena psychomotor koke. Eia nō naʻe, ma muli o ka hiki ʻana o ka dizziness, pono e hoʻomaʻemaʻe ʻia i ka wā e hoʻomaʻamaʻa ana i nā hana o luna.

ʻŌpū a me ka lactation

I ka wā o ka papa hana, pono nā wahine o ka wā hānau i ka hoʻohana ʻana iā Liprimar e hoʻohana i nā contraceptives kūpono. ʻO ke kumu o ka lāʻau lapaʻau, contraindicated i nā maʻi i pale ʻole ʻia mai ka wā hapai. Aia ka ʻike e pili ana i nā hihia lohi o nā anomalen congenital ma hope o ka hoʻolahaʻana i ka intrauterine i ka HMG-CoA reductase inhibitors (statins) ma ka pūpū. Ua hōʻoia ka noiʻi holoholona holoholona i kahi hopena oona i ka lulu.

He mea hiki ʻole ke kuhikuhi i ka Liprimar i nā makuahine hānai, no ka mea ʻaʻohe ʻike pono e pili ana i ka komo ʻana o ka atorvastatin i loko o ka waiū umauma. Inā pono e hoʻohana i ka lāʻau lapaʻau i ka wā lactation, pono ke hoʻopau ʻia ka ʻōpoki, i pale ʻole i ka hopena o ka hopena ʻole i nā pēpē.

Hoʻohana i ke wā kamaliʻi

Ma ka hoʻomaʻamaʻa pediatric, ua contraindicated ʻo Liprimar no ka mālama ʻana i nā keiki a me nā ʻōpio ma lalo o ka 18 makahiki o ka makahiki, ma muli o ka hemahema o ka ʻikepili lapaʻau e pili ana i ka hopena a me ka palekana o ka lapaʻau i kēia mau makahiki. ʻO kahi meaʻokoʻa loa ka mālama ʻia ʻana o ka hypercholesterolemia pamilya heterozygous, ka mea e hōʻike ana i ka hoʻohana ʻana o ka atorvastatin i nā keiki mai 10 mau makahiki o kona mau makahiki.

Me ka hana pūpū hemahema

Ua contraindicated e lawe i ka lāʻau lapaʻau no nā poʻe maʻi me nā maʻi o ka puʻuwai ma ka hana ikaika, a me ka piʻi ʻana o ka hana o ka hepatic transaminases o ka ʻike kumu ʻole i ka kaila koko ma mua o 3 mau manawa i hoʻohālikelike ʻia me ka palena palena kiʻekiʻe o ka maʻamau.

Me ka mālama aka, ua kuhikuhi ʻia ʻo Liprimar i nā poʻe maʻi e loaʻa nei i ka mōʻaukala o nā maʻi pepeka a me / a i ʻole nā ​​mea hōʻino kino.

Hoʻohana i ka wā kahiko

I ka wā e hoʻohana ai iā Liprimar i nā maʻi maʻi ʻelemakule, ʻaʻohe ʻokoʻa o ka palekana a me ka hoʻopiʻi ʻana i hoʻohālikelike ʻia me ka lehulehu kanaka i maopopo, no laila, ʻaʻohe mea pono o ka hoʻoponopono hoʻoponopono ʻana.

Ma ka hoʻonui ʻia o ka loaʻa ʻana o ka rhabdomyolysis i nā makahiki he 70, e pono e hoʻohana ʻia ʻo Liprimar me ka akahele.

Hoʻohui nūhou

Me ka hoʻohana like ʻana o Liprimar me kekahi mau lāʻau lapaʻau, hiki i nā hopena aʻe ke ʻano nei:

• Cyclosporin, fibrates, erythromycin, clarithromycin, antifungal drug (azole derivatives) a me ka hoʻōla o ka nikotinikika ma nā kūmole hypolipidemic: i hoʻonui nui ʻia o ka myopathy,
• CYP3A4 inhibitors isoenzyme: hoʻonui i ka hoʻohui o ka plasma o ka atorvastatin,
• OATP1B1 inhibitors (e.g., cyclosporine): hoʻonui bioavailability o atorvastatin,
• Erythromycin, clarithromycin, CYP3A4 inhibitors, diltiazem, grapefruit wai: hoʻonui i ke kukuna plasma o ka atorvastatin,
• Itraconazole: hoʻonui i ka AUC (ka nui o ke kaila plasma i kahi mea) a atorvastatin,
• ʻO nā mea hoʻohālikelike o ka cytochrome CYP3A4 isoenzyme: kahi hoʻohaʻahaʻa i ka uha o ka atorvastatin i loko o ke koko koko,
• Colestipol: kahi hōʻemi i ka neʻe o ka atorvastatin i ka plasma, akā naʻe, i ka hopena lipid-hoʻohaʻahaʻa ʻana o ka hui o nā lāʻau lapaʻau i ʻoi aku ma mua o kēlā me kēia,
• Digoxin: kahi hoʻonui i kona neʻe ʻana i ka wā e lawe ai iā Liprimar i nā koina kiʻekiʻe (pono ia e nānā i nā kūlana o nā mea maʻi),
• Nā maʻi hoʻohālikelike i pili i ka norethisterone a me ka ethinyl estradiol: i hoʻonui ʻia ʻo AUC o kēia mau mea.

Nā hui hoʻohālikelike o Liprimar i: Atorvastatin, Atorvastatin-Teva, Atoris, Liptonorm, Torvakard, Atorvoks, Tribestan, Krestor.

Nā Hōʻikeʻike Liprimar

Hoʻomaʻamaʻa pinepine ʻia ka lāʻau lapaʻau i nā poʻe maʻi e hōʻeha nei i nā pilikia like ʻole i ka hana o ke ʻōnaehana cardiovascular. Aia kekahi o nā loiloi e pili ana i ka Liprimar, no ka nui o nā mea maʻi e hōʻike nei i nā hana lapaʻau kiʻekiʻe kiʻekiʻe. Akā naʻe, ʻaʻole maopopo iki kekahi mau mea pehea e lawe ai i ka lāʻau lapaʻau ma muli o ka lawa ʻole o ka wehewehe ʻana i ka regimen lapaʻau e nā kauka. No laila, hoʻāʻo lākou e koho kūʻokoʻa a hoʻoponopono i nā hemahema o ka atorvastatin, ka mea e alakaʻi ai i ke ʻano o nā hopena maikaʻi ʻole (ka ulu ʻana o ke kī a me ka bruising, ke koko ʻana o ke koko, etc.).

Manaʻo nā loea i ka Liprimar kekahi o nā lāʻau lapaʻau ikaika loa i hāʻawi ʻia i nā kaha a me nā lōʻihi o ka papa o ka lapaʻau e mālama pono ʻia. Pono lākou i ka wā e mālama ai i ka hoʻōla kino kūpono hiki, hoʻomaʻamaʻa i ka papaʻai a hana pinepine i kahi mahele koko.

Pehea e lawe ai i ka Liprimar 10

Ua kuhikuhi ʻia nā papa no ka hoʻokele waha, me ka manawa o ka lā a me ka pāʻina paha. Lawe ʻia ka lāʻau lapaʻau me ka hana ʻole ʻana o ka meaʻai hypocholesterolemic, ke kaupaona ʻana i ke kaupaona kūʻē ʻana i ke ʻano o ke aniani o ka morbid, hoʻomaʻamaʻa. Inā hoʻonui ka hoʻonui ʻana i ka cholesterol ma lalo o ka maʻi i lalo, ma mua o ka hoʻohana ʻana iā Liprimar, pono ʻoe e hoʻāʻo e kāpae i ke kaʻina pili nui. I ka wā o ka papa lapaʻau holoʻokoʻa holoʻokoʻa, pono ʻoe e pili i ka meaʻai kūikawā.

Ke lawe ʻia nei ka lāʻau lapaʻau me Liprimar 10 me ka hoʻopiʻi ʻole ʻana o ka meaʻai hypocholesterolemic.

ʻO ka mahele o kēlā me kēia lā he 10-80 mg no ka hoʻohana hoʻokahi a ua hoʻoponopono ʻia ma muli o ka hana o LDL-C a ma ka loaʻa ʻana o ka hopena therapeutic.

ʻO ka dosage kiʻekiʻe e ʻae ʻia he 80 mg.

I ka wā o ka mālama ʻana me Liprimar, pono ia e nānā i ka mālama ʻana o ka plasma o nā lipids i kēlā me kēia mau hebedoma 2-4, ma hope o ia mea e pono ai ʻoe e nīnau i kāu kauka e pili ana i nā loli i ka noho hoʻoponopono ʻia.

E hoʻopau i ka ʻano o ka hyperlipidemia i hui ʻia, pono ia e lawe i ka 10 mg hoʻokahi i ka lā hoʻokahi, ʻoiai he hypercholesterolemia mana homozygous e koi i ka nui o ka therapeutic dosis o 80 mg. I ka hopena hope, hoʻemi ʻia ka nui o ka cholesterol ma o 20-45%.

Lawe i ka lāʻau lapaʻau no ka maʻi maʻi maʻi

ʻO nā mea maʻi me ka maʻi maʻi maʻi e akahele i ka wā e hele ai ka hypercholesterolemia. Holoi kēlā mau kānaka i ka hoʻomohala ʻana i ka maʻi naʻau coronary. Hoʻohana ʻia ka liprimar i ke ʻano o ka pale ʻana i ka infarction myocardial. Ua hoʻoholo ʻia ka nui o ka hewa e ke kauka hele ʻana ma muli o ka pae o ka cholesterol.

ʻO nā mea maʻi me ka maʻi maʻi maʻi e akahele i ka wā e hele ai ka hypercholesterolemia.

Pūnaehana pīhoihoi waena

Hōʻike maikaʻi ka hopena me ka hōʻino ʻana i ka ʻōnaehana hae e like me:

• ʻōpala
• malekilima
• ʻālaʻaka aseic
• hōʻeha a me ka ʻōpū,
• hōʻemi a hoʻopau i ka nānāʻana,
• peripheral nerve neuropathy,
• amnesia.

Mai ka papa huhū

Hiki paha i ke Dyspnea.

Me ka hopena e hōʻike i nā hopena anaphylactic, rashes ma ka ʻili, ʻulaʻula, ʻaina, erythema exudative, necrosis o ka momona momona subcutaneous. Ma nā hihia koʻikoʻi, hoʻomohala ka edema a Quincke a me ka pīhoihoi anaphylactic.

Ma mua o ka lāʻau i loko o ka nīnau e hoʻonāukiuki i ke ʻano o nā rashes ma ka ʻili.

Hoʻolaha ka waipuna

ʻAʻole pono e kāwili ʻia ka lāʻau lapaʻau me ka inu ʻaka. Hoʻopili ka Ethyl alkohol i ke kaila waena, hepatobiliary a me ka ʻōnaehana uila, a no laila ua hoʻemi ʻia ka hopena hypocholesterolemic o Liprimar. Hiki i ke kūpaʻa o ka hoʻokumu ʻana i nā pāla atherosclerotic ma nā paia o ke kīʻaha koko.

ʻAʻole pono e kāwili ʻia ka lāʻau lapaʻau me ka inu ʻaka.

ʻAʻole hiki ke hoʻohui ʻia ʻana

Ma muli o ka hopena o ka pilikia neuromuscular pathologies, ʻaʻole i ʻōlelo ʻia ʻo ka lawelawe ʻokoʻa i ka liprimar:

• Pākoʻomaʻo cyclosporin
• nikolinic acid derivatives,
• Erythromycin
• lāʻau lapaʻau antifungal
• nā huaʻai.

Hoʻokomo ʻia ka hoʻokele ʻana o Liprimar a me Erythromycin.

ʻO kēlā mau hui lāʻau hiki ke alakaʻi i myopathy.

Me ka mālama pono

A ʻoi ʻia e akahele aka me ka hoʻohana ʻana iā Liprimar me nā lāʻau lapaʻau ʻē aʻe.

• Hiki i ke Atorvastatin ke hoʻonui i ka AUC o nā mea hoʻohālikelike waha i ka 20-30%, hilinaʻi i nā hormones i loaʻa i ka hoʻomākaukau.
• Atorvastatin me kahi papa o 40 mg o ka hui pū me ka 240 mg o Diltiazem alakaʻi i kahi hoʻonui o ke kaila plasma o ka atorvastatin i ke koko. I ka lawe ʻana o 200 mg o Itraconazole me 20-40 mg o Liprimar, ʻike ʻia kahi hoʻonui o AUC o atorvastatin.
• Hoʻopili ke Rifampicin i nā pae plasma o atorvastatin.
• ʻO Colestipol ka mea e hōʻemi ai i ka lālani plasma-hoʻemi haʻahaʻa.
• Me ka hui pū me ka digoxin, ʻoi ka ʻike ʻana o ka hopena ma hope o 20%.

Hoʻopake i ka wai kīloi i ka hana a ka isoenzyme o ka cytochrome CYP3A4, ʻo ia ke kumu a inu i ke kakano o ka wai o ka citrus i kēlā lā i kēia lā, hoʻonui ʻia ka plasma o ka atorvastatin. Loaʻa kekahi hopena like i ka wā e lawe ai i nā inhibitor CYP3A4 (Ritonavir, Ketoconazole).

ʻAʻole pāpā ʻia ʻo Liprimar e hoʻohana i nā wahine hāpai 10.

Hoʻohana i ka wā hāpai a me ka lactation

Lā ʻia ka hoʻohana ʻana i ka lāʻau lapaʻau no nā wahine hāpai, ʻoiai aia kekahi hewahewa o ka hala ʻole o ka waiho pololei ʻana o nā ʻili a me nā ʻoka i ka wā o ka hoʻolālā ʻana o ka embryonic. ʻAʻohe ʻikepili ma ka hiki i Liprimar e komo i ka halihā hematoplacental.

I ka wā o ka lāʻau lapaʻau, pono e hoʻopau ʻia ka umauma.

ʻO nā mea hoʻohālikelike o ka lāʻau e loaʻa ai nā hopena like ʻole:

Hoʻololi ʻia ka pau ma hope o ke kūkā kamaʻilio maʻi.

He wikiō hoʻolaha a "Liprimar" aʻo aʻoaʻo Liprimar

ʻLoe a me ke kākele

Ma mua o ke kuhikuhi ʻana i ka Liprimar, pono ia e hoʻokō i ka hoʻopaʻa o ka hypercholesterolemia me ka mālama ʻana i ka maʻi mākaʻikaʻi ʻia, a me nā ʻano ʻē aʻe non-pharmacological (kaʻaiʻai, kaʻai ʻana a me ka hoʻolilo ʻana i ke kaumaha ma nā mea maʻi me ka momona).

I ka wā o ka lāʻau lapaʻau, ua kauoha ʻia ka mea maʻi e hahai i kahi laʻa maʻamau hypocholesterolemic.

Kuhi ʻia ka liprimar no ka hoʻoponopono waha ʻana, me ka ʻole o ka manawa o ka lā a me ka pāʻina paha.

Hoʻololi ka ʻōhua mai ka 10 a 80 mg i hoʻokahi lā. Hoʻoholo ʻia ka koho Dose me ka manaʻo e pili ana i ka haʻahaʻa koloprotein cholesterol haʻahaʻa haʻahaʻa (LDL-C), ka hopena pilikino a me ke kumu o ka mālama ʻana. ʻO ka palena loa ma kēlā me kēia lā he 80 mg hoʻokahi.

I ka hoʻomaka ʻana o ka pena, me ka piʻi ʻana o nā dosis, he pono no ka hoʻoholo ʻana o ka neʻe ʻana o nā lipids i ka plasma i kēlā me kēia mau hebedoma 2-4, a me ka noʻonoʻo ʻana i ka ʻike i loaʻa, e hoʻoponopono i ka ʻōpala.

Me ka hoʻohui (hui pū ʻia) hyperlipidemia a me hypocholesterolemia mua, ʻo ka nui o ka make o Liprimar no ka hapa nui o nā maʻi he 10 mg hoʻokahi i ka lā. Hōʻike ʻia ka hopena therapeutic i loko o nā hebedoma mua a hiki i ke kiʻekiʻe nui e nā 4 wiki o ka mālama ʻana. Me ka hopena lōʻihi, hoʻomau ka hopena.

ʻO ka poʻe maʻi me ka homozygous hypercholesterolemia Liprimar e kuhikuhi ʻia i loko o kahi maʻa o 80 mg hoʻokahi i hoʻokahi lā (ʻo ka pae o LDL-C e hōʻemi ana i ka 18-45%).

I ka hihia o ka hana renal impaired a me ka poʻeʻelemakule, ʻaʻole pono nā hoʻoponopono hoʻoponopono ʻana.

I ka hana ole o ka ate, hoʻemi ʻia ka nui o ka ma lalo o ka mālama mau ʻana o ka hana a nā enzymes alanine aminotransferase a aspartate aminotransferase.

Me ka hana like me ka cyclosporine, ʻaʻole eʻoi aku ka nui o ka make o Liprimar i ka 10 mg i kēlā me kēia lā.